1. Issue Highlights Clinical Gastroenterology and Hepatology
Jonathan M. Buscaglia, MD, AGAF 
Clinical Gastroenterology and Hepatology 
Volume 14, Issue 10, Pages (October 2016)
DOI: /j.cgh
Copyright © 2016 AGA Institute Terms and Conditions

2. Figure 1
Significant dose-response association between EOT HBsAg level and clinical (A) and virologic (B) relapse in patients with negative HBeAg at the end of treatment.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

3. Figure 2
Cumulative probability to remain IC during follow-up given HBsAg at inclusion. *HBsAg 100–1000 IU/mL versus >1000 IU/mL: HR, 0.61; 95% CI, 0.3–1.2; P = Two IC patients did not have further follow-up beyond Year 1.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

4. Figure 3
Meta-regression analysis. BMI (X axis) was plotted against the estimated pooled effect of the intervention on intrahepatic lipid level (SMD, Y axis). The more negative the SMD value, the more effective the intervention at lowering intrahepatic lipids. P = This analysis was robust even after removing the outlier (Hallsworth et al24).
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions